Rabbit Recombinant Monoclonal Interferon beta antibody - conjugated to Biotin. Suitable for sELISA and reacts with Human samples.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
| sELISA | |
|---|---|
| Human | Expected |
| Species | Dilution info | Notes |
|---|---|---|
Species Human | Dilution info Use at an assay dependent concentration. | Notes - |
Type I interferon cytokine that plays a key role in the innate immune response to infection, developing tumors and other inflammatory stimuli (PubMed:10049744, PubMed:10556041, PubMed:6157094, PubMed:6171735, PubMed:7665574, PubMed:8027027, PubMed:8969169). Signals via binding to high-affinity (IFNAR2) and low-affinity (IFNAR1) heterodimeric receptor, activating the canonical Jak-STAT signaling pathway resulting in transcriptional activation or repression of interferon-regulated genes that encode the effectors of the interferon response, such as antiviral proteins, regulators of cell proliferation and differentiation, and immunoregulatory proteins (PubMed:10049744, PubMed:10556041, PubMed:7665574, PubMed:8027027, PubMed:8969169). Signals mostly via binding to a IFNAR1-IFNAR2 heterodimeric receptor, but can also function with IFNAR1 alone and independently of Jak-STAT pathways (By similarity). Elicits a wide variety of responses, including antiviral and antibacterial activities, and can regulate the development of B-cells, myelopoiesis and lipopolysaccharide (LPS)-inducible production of tumor necrosis factor (By similarity). Plays a role in neuronal homeostasis by regulating dopamine turnover and protecting dopaminergic neurons: acts by promoting neuronal autophagy and alpha-synuclein clearance, thereby preventing dopaminergic neuron loss (By similarity). IFNB1 is more potent than interferon-alpha (IFN-alpha) in inducing the apoptotic and antiproliferative pathways required for control of tumor cell growth (By similarity).
IFB, IFNB, IFNB1, Interferon beta, IFN-beta, Fibroblast interferon
Rabbit Recombinant Monoclonal Interferon beta antibody - conjugated to Biotin. Suitable for sELISA and reacts with Human samples.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for the Abcam trial program.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Interferon beta also known as IFN-beta or beta interferon is a type I interferon with a mass of approximately 20 kDa. It originates primarily from fibroblasts and plays an essential role in the immune response. This protein targets and binds to specific cell surface receptors initiating various antiviral states within cells. This action assists in slowing down viral replication and spread. IFN-beta's expression increases in response to viral infections making it an important component in the body's first line of defense against pathogens.
Interferon beta functions as an important mediator of immune functions regulating the activity of natural killer cells and macrophages. It also boosts antigen presentation to T cells. Interferon beta belongs to the larger family of interferons which includes IFN-alpha and IFN-gamma each having distinct effects but working together to mount an effective immune response. Though it does not form part of a complex it plays a critical standalone role in immune signaling pathways.
Interferon beta associates strongly with the JAK-STAT signaling pathway. Upon activation it interacts with receptors to phosphorylate STAT proteins mainly STAT1 and STAT2 which then dimerize and translocate to the nucleus to trigger gene expression. Another important pathway is the antiviral response where interferon beta modulates the expression of hundreds of interferon-stimulated genes. These pathways intricately involve other proteins like IFN-alpha and IFN-gamma which work synergistically to establish an effective antiviral environment.
Interferon beta shows significant implications in multiple sclerosis and hepatitis C infection. It is widely used as a therapeutic agent in managing multiple sclerosis by modulating the immune response to reduce inflammation and slow disease progression. Similarly its role in antiviral defense makes it relevant to hepatitis C infection management. In these contexts IFN-alpha and IFN-gamma are also important as they share similar antiviral and immunomodulatory functions that can complement IFN-beta's actions enhancing the treatment's efficacy.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com